CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...

-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...

How CRISPR and functional genomics are used to establish causality, understand disease mechanisms and guide early drug ...

-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the ...

Presentations will showcase the company’s latest advances enabled by its CRISPR by Design TM approach to engineer safer and more effective in vivo genetic medicines for cardiometabolic disease ALAMEDA ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (“Scribe”), a genetic medicines company pioneering next-generation in vivo CRISPR-based medicines designed to be safe, durable, and effective ...

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

Oceanic ecosystems are increasingly threatened by global warming, which causes coral bleaching, species migration and, ...